AUTHOR AND EDITOR INFORMATION
Section 1 of 9
Author: Stefano Guandalini, MD, Director, University of Chicago Celiac Disease Program, Section Chief of Gastroenterology, Hepatology and Nutrition; Professor, Department of Pediatrics, University of Chicago Comer Children's Hospital
Stefano Guandalini is a member of the following medical societies: American Gastroenterological Association, European Society for Paediatric Gastroenterology, Hepatology & Nutrition, and North American Society for Pediatric Gastroenterology and Nutrition
Coauthor(s):
Richard E Frye, MD, PhD, Assistant Professor, Departments of Pediatrics and Neurology, University of Texas Health Science Center at Houston;
M Akram Tamer, MD, Program Director, Professor, Department of Pediatrics, University of Miami
Editors: Chris A Liacouras, MD, Director of Pediatric Endoscopy, Department of Pediatrics, Division of Gastroenterology and Nutrition, Associate Professor, Children's Hospital of Philadelphia and University of Pennsylvania; Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine.com, Inc; Steven M Schwarz, MD, FAAP, FACN, AGAF, Professor of Pediatrics, State University of New York, Downstate Medical Center College of Medicine; Distinguished Lecturer, New York Medical College, School of Public Health; Carmen Cuffari, MD, Associate Professor, Department of Pediatrics, Division of Gastroenterology/Nutrition, Johns Hopkins University School of Medicine
Author and Editor Disclosure
Synonyms and related keywords:
diarrhea, loose stool, runny stool, fluid stool, acute gastroenteritis, traveler's diarrhea, dysentery, dehydration, childhood diarrhea, malabsorption, malabsorption syndrome, acute-onset diarrhea, inflammatory bowel disease, irritable bowel syndrome, toddler's diarrhea, viral diarrhea, rotavirus, adenovirus, astrovirus, calicivirus, yersinia enterocolitis, Yersinia enterocolitica, Aeromonas, Shigella, Escherichia coli, E coli, Clostridium, Salmonella, Giardia, Cryptosporidium, Entamoeba
Background
Acute diarrhea is defined as the abrupt onset of abnormally high fluid content in the stool (more than the normal value of approximately 10 mL/kg/d). This situation usually implies an increased frequency of bowel movements, which can range from 4-5 to more than 20 times per day. The augmented water content in the stools is due to an imbalance in the physiology of the small and large intestinal processes involved in the absorption of ions, organic substrates, and water. A common disorder in its acute form, diarrhea has many causes and may be mild to severe. Childhood acute diarrhea is usually caused by infection; however, a number of disorders may cause this condition, including a malabsorption syndrome and various enteropathies. Acute-onset diarrhea is usually self-limited; however, an acute infection can have a protracted course. By far, the most common complication of acute diarrhea is dehydration.
Pathophysiology
Viruses directly damage the small intestinal villi, thereby decreasing intestinal surface area and unmasking ongoing fluid secretion by enteric crypts. Furthermore, rotavirus produces an enterotoxin that possibly induces secretion and contributes to the watery diarrhea. Bacteria may cause diarrhea by several different mechanisms. Invasive bacteria cause mucosal ulceration and abscess formation with a concomitant inflammatory response. Bacterial toxins may influence enteral and extraenteric cellular processes. For example, the heat-labile and heat-stable enterotoxins of Escherichia coli activate enteral adenylate cyclase and guanylate cyclase, respectively. Verotoxin, which is produced by enterohemorrhagic E coli and Shigella species, may cause systemic disorders, such as seizures and hemolytic uremic syndrome (HUS), if absorbed. Other noninvasive bacteria and protozoa adhere to the gut wall, causing inflammation.
Noninfectious causes of diarrhea include disorders of intestinal digestive and/or absorptive processes, congenital disorders and enteropathies, endocrine abnormalities, hormone-secreting tumors, pancreatic and liver dysfunction, anatomic abnormalities, inflammatory bowel disease, and irritable bowel syndrome (also called toddler's diarrhea in individuals aged 6 mo to 3 y). These noninfectious abnormalities may have other systemic signs and symptoms and should be considered if an acute-onset diarrhea fails to resolve within 14 days or if the condition recurs.
Frequency
United States
In the United States, 1 episode per child per year is estimated to occur in children younger than 5 years, with 220,000 hospital admissions (about 10% of all admissions for children in this age range) and about 400 deaths per year. Furthermore, acute diarrhea apparently causes 20% of referrals to physicians for children younger than 2 years and 10% for children younger than 3 years.
International
In developing countries, an average of 3 episodes per child per year in children younger than 5 years has been reported, but some areas have been reported to have 6-8 episodes per child per year. In these settings, malnutrition plays an additional and important negative role by exposing children to a higher risk of acute and prolonged diarrhea.
Mortality/Morbidity
Despite important progress made in the past decade, worldwide mortality remains high, with approximately 2 million deaths per year, according to a World Health Organization (WHO) estimate.
- Diarrhea is so common that individuals outside of clinical practice may disregard potential mortality and morbidity.
- As mentioned, about 2 million children worldwide (almost entirely from developing countries) are estimated to die each year because of diarrheal illness, making the condition the second most common cause of death in children, after respiratory infections.
Sex
- Most cases of infectious diarrhea are not sex specific.
- Females have a higher incidence of Campylobacter species infections and HUS.
- Among conditions associated with chronic diarrhea, celiac disease is slightly more common in females.
Age
- Viral diarrhea is most common in young children. Rotavirus and adenovirus are particularly prevalent in children younger than 2 years. Astrovirus and calicivirus usually infect children younger than 5 years.
- Yersinia enterocolitis typically infects children younger than 1 year, and the Aeromonas organism is a significant cause of diarrhea in young children.
- Very young children are particularly susceptible to secondary dehydration and secondary nutrient malabsorption.
History
- Diarrhea generally implies an increase in stool volume and diminished stool consistency.
- In children younger than 2 years, diarrhea is defined as daily stools with a mass greater than 10 mL/kg.
- In children older than 2 years, diarrhea is defined as daily stools with a mass greater than 200 g. In practice, this typically means loose-to-watery stools passed 4 or more times per day.
- Individual stool patterns vary widely; for example, breastfed children normally may have 5-6 stools per day.
- Abnormally watery stools may be the only symptom in some individuals with diarrhea.
- Flatulence associated with foul-smelling stools that float suggests fat malabsorption, which can be observed with infection with Giardia lamblia.
- Knowledge of the characteristics of consistency, color, volume, and frequency can be helpful in determining whether the source is from the small or large bowel. Table 1 outlines these characteristics and demonstrates that an index of suspicion can be easily generated for a specific set of organisms.
Table 1. Stool Characteristics and Determining Their Source Stool Characteristics | Small Bowel | Large Bowel | Appearance | Watery | Mucoid and/or bloody | Volume | Large | Small | Frequency | Increased | Highly increased | Blood | Possibly positive but never gross blood | Commonly grossly bloody | pH | Possibly <5.5 | >5.5 | Reducing substances | Possibly positive | Negative | WBCs | <5/high power field | Commonly >10/high power field | Serum WBCs | Normal | Possible leukocytosis, bandemia | Organisms | Viral | Invasive bacteria | | Enterotoxigenic bacteria | Toxic bacteria | | Parasites | Parasites |
- Associated systemic symptoms include the following:
- Some enteric infections commonly have systemic symptoms, whereas others less commonly are associated with systemic features.
- Table 2 outlines the frequency of some of these symptoms with particular organisms.
- Onset and duration is as follows:
- A history of contact with unhealthy individuals, particular food exposures, or travel history may suggest a causative organism.
- Table 2 outlines incubation periods and usual duration of symptoms of common organisms. Certain organisms (eg, C difficile, Giardia, Entamoeba species) may be associated with a protracted course.
Table 2. Organisms and Frequency of Symptoms Organism | Incubation | Duration | Vomiting | Fever | Abdominal Pain | Rotavirus | 1-7 days | 4-8 days | Yes | Low | No | Adenovirus | 8-10 days | 5-12 days | Delayed | Low | No | Norwalk virus | 1-2 days | 2 days | Yes | No | No | Astrovirus | 1-2 days | 4-8 days | +/- | +/- | No | Calicivirus | 1-4 days | 4-8 days | Yes | +/- | No | Aeromonas species | None | 0-2 weeks | +/- | +/- | No | Campylobacter species | 2-4 days | 5-7 days | No | Yes | Yes | C difficile | Variable | Variable | No | Few | Few | C perfringens | Minimal | 1 day | Mild | No | Yes | Enterohemorrhagic E coli | 1-8 days | 3-6 days | No | +/- | Yes | Enterotoxigenic E coli | 1-3 days | 3-5 days | Yes | Low | Yes | Plesiomonas species | None | 0-2 weeks | +/- | +/- | +/- | Salmonella species | 0-3 days | 2-7 days | Yes | Yes | Yes | Shigella species | 0-2 days | 2-5 days | No | High | Yes | Vibrio species | 0-1 day | 5-7 days | Yes | No | Yes | Yersinia enterocolitica | None | 1-46 days | Yes | Yes | Yes | Giardia species | 2 weeks | 1+ weeks | No | No | Yes | Cryptosporidium species | 5-21 days | Months | No | Low | Yes | Entamoeba species | 5-7 days | 1-2+ weeks | No | Yes | No |
Table 4. Organisms Associated With Travel | Foreign Travel History | Organism | Nonspecific | Enterotoxigenic E coli, Aeromonas, Giardia, Plesiomonas, Salmonella, and Shigella species | Underdeveloped tropics | C perfringens | Africa | Entamoeba species, Vibrio cholerae | South and Central America | Entamoeba species, V cholerae, enterotoxigenic E coli | Asia | V cholerae | Australia | Yersinia species | Canada | Yersinia species | Europe | Yersinia species | India | Entamoeba species, V cholerae | Japan | Vibrio parahaemolyticus | Mexico | Aeromonas, Entamoeba, Plesiomonas, and Yersinia species | New Guinea | Clostridium species |
- Animal exposure can contribute to diarrhea.
- Exposure to young dogs or cats is associated with Campylobacter organisms.
- Exposure to turtles is associated with Salmonella organisms.
- Certain medical conditions predispose patients to infection. Table 5 outlines such medical conditions and their associated organisms.
Table 5. Medical Conditions That Predispose Individuals to Diarrhea Organism | Comorbid Risk Factors | C difficile | Hospitalization, antibiotic administration | Plesiomonas species | Liver diseases or malignancy | Salmonella species | Intestinal dysmotility, malnutrition, achlorhydria, hemolytic anemia (especially sickle cell disease), immunosuppression, malaria | Rotavirus | Hospitalization | Giardia species | Agammaglobulinemia, chronic pancreatitis, achlorhydria, cystic fibrosis | Cryptosporidia species | Immunocompromised or immunosuppressed state |
Physical
- Dehydration
- Dehydration is the principal cause of morbidity and mortality.
- Assess every patient with diarrhea for signs, symptoms, and severity.
- Lethargy, depressed consciousness, sunken anterior fontanel, dry mucous membranes, sunken eyes, lack of tears, poor skin turgor, and delayed capillary refill are obvious and important signs of dehydration.
- Failure to thrive and malnutrition
- Reduced muscle and fat mass or peripheral edema may be clues to the presence of carbohydrate, fat, and/or protein malabsorption.
- Giardia organisms can cause intermittent diarrhea and fat malabsorption.
- Abdominal pain
- Nonspecific nonfocal abdominal pain and cramping are common with some organisms.
- Pain usually does not increase with palpation.
- With focal abdominal pain worsened by palpation, rebound tenderness, or guarding, be alert for possible complications or for another noninfectious diagnosis.
- Borborygmi: Significant increases in peristaltic activity can cause an audible and/or palpable increase in bowel activity.
- Perianal erythema
- Frequent stools can cause perianal skin breakdown, particularly in young children.
- Secondary carbohydrate malabsorption often results in acidic stools.
- Secondary bile acid malabsorption can result in a severe diaper dermatitis that is often characterized as a "burn."
Causes
- Viruses
- Rotavirus is by far the single most common cause of infectious diarrhea worldwide.
- Rotavirus infection accounts for 33% of hospitalizations and 20% of deaths associated with infectious gastroenteritis.
- Rotavirus is prevalent throughout the year; however, peak incidence occurs in the winter months.
- Adenovirus is the second most common cause of viral gastroenteritis in hospitalized children.
- Bacteria
- Salmonella, Shigella, and Campylobacter organisms are the 3 most common causes of bacterial diarrhea in children worldwide, with Aeromonas organisms a close fourth.
- Infections with Aeromonas and Shigella organisms are most common during the summer and fall seasons.
- Infections with Campylobacter organisms typically occur during the summer months.
- Infections with Yersinia organisms occur most often during the winter months, particularly in colder climates.
Appendicitis
Carcinoid Tumor
Congenital Microvillus Atrophy
Crohn Disease
Cystic Fibrosis
Giardiasis
Hyperthyroidism
Intestinal Enterokinase Deficiency
Intestinal Protozoal Diseases
Intussusception
Irritable Bowel Syndrome
Malabsorption Syndromes
Meckel Diverticulum
Protein Intolerance
Shigella Infection
Short Bowel Syndrome
Ulcerative Colitis
Lab Studies
- A stool pH level of 5.5 or less or presence of reducing substances indicates carbohydrate intolerance, which is usually secondary to viral illness and transient in nature.
- Enteroinvasive infections of the large bowel cause leukocytes, predominantly neutrophils, to be shed into stool. Absence of fecal leukocytes does not eliminate the possibility of enteroinvasive organisms. However, presence of fecal leukocytes eliminates consideration of enterotoxigenic E coli, Vibrio species and viruses.
- Examine any exudates found in stool for leukocytes. Such exudates highly suggest colitis (80% positive predictive value). Colitis can be infectious, allergic, or part of inflammatory bowel disease (Crohn disease, ulcerative colitis).
- Many different culture mediums are used to isolate bacteria (see Table 7). Table 6 lists common bacteria and optimum culture mediums for their growth. A high index of suspicion is needed to choose the appropriate medium.
- With stool not cultured within 2 hours of collection, refrigerate at 4°C or place in a transport medium. Although stool cultures are useful when positive, yield is low.
- Always culture stool for Salmonella, Shigella, and Campylobacter organisms and Y enterocolitica in the presence of clinical signs of colitis or if fecal leucocytes are found.
- Look for C difficile in persons with episodes of diarrhea characterized by colitis and/or blood in the stools. Remember that acute-onset diarrheal episodes associated with C difficile may also occur without a history of antibiotic use.
- Bloody diarrhea with a history of ground beef ingestion must raise suspicion for enterohemorrhagic E coli. If E coli is found in the stool, determine if the type of E coli is O157:H7. This type of E coli is the most common, but not only, cause of HUS.
- History of raw seafood ingestion or foreign travel should prompt additional screening for Vibrio and Plesiomonas species.
Table 6. Common Bacteria and Optimum Culture Mediums Organism | Detection Method | Microbiologic Characteristics | Aeromonas species | Blood agar | Oxidase-positive flagellated gram-negative bacillus (GNB) | Campylobacter species | Skirrow agar | Rapidly motile curved gram-negative rod (GNR); Campylobacter jejuni 90% and Campylobacter coli 5% of infections | C difficile | Cycloserine-cefoxitin-fructose-egg (CCFE) agar; enzyme immunoassay (EIA) for toxin; latex agglutination (LA) for protein | Anaerobic spore-forming gram-positive rod (GPR); toxin-mediated diarrhea; produces pseudomembranous colitis | C perfringens | None available | Anaerobic spore-forming GPR; toxin-mediated diarrhea | E coli | MacConkey eosin-methylene blue (EMB) or Sorbitol-MacConkey (SM) agar | Lactose-producing GNR | Plesiomonas species | Blood agar | Oxidase-positive GNR | Salmonella species | Blood, MacConkey EMB, xylose-lysine-deoxycholate (XLD), or Hektoen enteric (HE) agar | Nonlactose non–H2S-producing GNR | Shigella species | Blood, MacConkey EMB, XLD, or HE agar | Nonlactose and H2S-producing GNR; verotoxin (neurotoxin) | Vibrio species | Blood or thiosulfate-citrate-bile-salts-sucrose (TCBS) agar | Oxidase-positive motile curved GNB | Y enterocolitica | Cefsulodin-ingrasan-novobiocin (CIN) agar | Nonlactose-producing oval GNR |
Table 7. Culture Mediums Used to Isolate Bacteria Blood agar | All aerobic bacteria and yeast; detects cytochrome oxidase production | MacConkey eosin-methylene blue (EMB) agar | Inhibits gram-positive organisms; permits lactose fermentation | Xylose-lysine-deoxycholate (XLD) agar; Hektoen enteric (HE) agar | Inhibits gram-positive organisms and nonpathogenic GNB; permits lactose fermentation and H2S production | Skirrow agar | Selective for Campylobacter species | Sorbitol-MacConkey (SM) agar | Selective for enterohemorrhagic E coli | Cefsulodin-ingrasan-novobiocin (CIN) agar | Selective for Y enterocolitica | Thiosulfate-citrate-bile-sucrose (TCBS) agar | Selective for Vibrio species | Cycloserine-cefoxitin-fructose-egg (CCFE) agar | Selective for C difficile |
- Rotavirus antigen can be identified by enzyme immunoassay and latex agglutination assay of the stool. The false-negative rate is approximately 50%, and false-positive results occur, particularly in the presence of blood in the stools.
- Adenovirus antigens can be detected by enzyme immunoassay. Only serotypes 40 and 41 are able to induce diarrhea.
- Examination of stools for ova and parasites is best for finding parasites. Perform stool examination every 3 days or every other day.
- The leukocyte count is usually not elevated in viral-mediated and toxin-mediated diarrhea. Leukocytosis is often but not constantly observed with enteroinvasive bacteria. Shigella organisms cause a marked bandemia with a variable total white blood cell count.
- At times, a protein-losing enteropathy can be found in patients with extensive inflammation in the course of enteroinvasive intestinal infections (eg, Salmonella species, enteroinvasive E coli). In these circumstances, low serum albumin levels and high fecal alpha1-antitrypsin levels can be found.
Procedures
- Intestinal biopsy: This procedure may be indicated in the presence of chronic or protracted diarrhea, as well as in cases in which a search for a cause is believed to be mandatory (eg, in patients with acquired immunodeficiency syndrome [AIDS] or patients who are otherwise severely immunocompromised).
Medical Care
Because most infectious diarrhea is self-limiting, medical care is primarily supportive and aimed at maintaining hydration, treating dehydration, or both. Oral rehydration therapy (ORT) is the mainstay of treatment in all children with diarrhea; never neglect ORT, even in the absence of overt dehydration because maintaining hydration is necessary. Neonates and young infants are at high risk of secondary complications and require close monitoring. Consider intravenous rehydration only in the unlikely event that ORT is unsuccessful. - ORT is the cornerstone of treatment, especially for small-bowel infections that produce a large volume of watery stool output.
- Not all commercial ORT formulas promote optimal absorption of electrolytes, water, and nutrients.
- The ideal solution has a low osmolarity (210-250) and a sodium content of 50-60 mmol/L.
- Administer maintenance fluids plus replacement of losses. Educate caregivers in methods necessary to replace this amount of fluid.
- Administer small amounts of fluid at frequent intervals to minimize discomfort and vomiting.
- A 5-cc or 10-cc syringe without a needle is a very useful tool. The syringe can be used to quickly place small amounts of fluid in the mouth of a child who is uncooperative.
- Once the child becomes better hydrated, cooperation improves enough to take small sips from a cup. This method is time intensive and requires a dedicated caregiver.
- Encouragement from the physician is necessary to promote compliance.
- OR is now universally recommended to be completed in an expedite way, within 4 hours.
- At completion of hydration, resumption of feeding is recommended strongly. In fact, many studies convincingly demonstrate that early refeeding hastens recovery. Also, robust evidence suggests that, in the vast majority of episodes of acute diarrhea, refeeding can be accomplished without the use of any special (eg, lactose-free or soy-based) formulas.
- Antimotility agents are not indicated for infectious diarrhea, except for refractory cases of Cryptosporidium infection.
- Antimicrobial therapy is indicated for some nonviral diarrhea, since most is self-limiting and does not require therapy. Table 8 lists standard therapies.
Table 8. Therapies for Nonviral Diarrhea Aeromonas species | Use cefixime and most third- and fourth-generation cephalosporins. | Campylobacter species | Erythromycin shortens illness duration and shedding. | C difficile | Discontinue potential causative antibiotics. If antibiotics cannot be stopped or this does not result in resolution, use oral metronidazole or vancomycin. Vancomycin is reserved for the child who is seriously ill. | C perfringens | Do not treat with antibiotics. | Cryptosporidium parvum | Paromomycin; however, effectiveness is not proven. Nitazoxanide, a newer anthelmintic, is effective against C parvum. | Entamoeba histolytica | Metronidazole followed by iodoquinol or paromomycin Asymptomatic carriers in nonendemic areas: Iodoquinol or paromomycin | E coli | Trimethoprim-sulfamethoxazole (TMP-SMX) if moderate or severe; antibiotic treatment may increase likelihood of HUS. Parenteral second-generation or third-generation cephalosporin for systemic complications | G lamblia | Metronidazole or nitazoxanide can be used. | Plesiomonas species | Use TMP-SMX or any cephalosporin. | Salmonella species | Treatment prolongs carrier state, is associated with relapse, and is not indicated for nontyphoid-uncomplicated diarrhea. Treat infants younger than 3 months and high-risk patients (eg, immunocompromised, sickle cell disease). TMP-SMX is first-line medication; however, resistance occurs. Use ceftriaxone and cefotaxime for invasive disease. | Shigella species | Treatment shortens illness duration and shedding but does not prevent complications. TMP-SMX is first-line medication; however, resistance occurs. Cefixime, ceftriaxone, and cefotaxime are recommended for invasive disease. | V cholerae | Treat infected individuals and contacts. Doxycycline is the first-line antibiotic, and erythromycin is second-line antibiotic. | Yersinia species | TMP-SMX, cefixime, ceftriaxone, and cefotaxime are used. Treatment does not shorten disease duration; reserve for complicated cases. |
Consultations
- Surgeon
- Certain organisms cause abdominal pain and bloody stools.
- Symptoms resembling appendicitis, hemorrhagic colitis, intussusception, or toxic megacolon may be appreciated.
- If the infectious etiology in individuals with such symptoms is not certain, seek consultation with a surgeon.
- Infectious-disease specialist: Consider consultation with an infectious-disease specialist for any patient who is immunocompromised because of HIV infection, chemotherapy, or immunosuppressive drugs, since atypical organisms are more likely, and complications can be more serious and fulminate.
Diet
- Bananas, rice, applesauce, and toast diet
- A banana, rice, applesauce, and toast (BRAT) diet has been recommended for years.
- However, no evidence shows that this diet is useful, and its poor protein content may be a contraindication; therefore, do not recommend a BRAT diet.
- A strong body of evidence now suggests that resuming the prediarrhea diet is perfectly safe and must be encouraged, obviously respecting any (usually temporary) lack of appetite.
- Lactose ingestion
- Although rotavirus can cause secondary transient lactose intolerance, this finding is believed to be generally not clinically relevant; use lactose-containing formulas in all individuals with diarrhea.
- In an incident of worsening of diarrhea proven to be secondary to a clinically important lactose malabsorption in infants positive for rotavirus, a very transient use of lactose-free formulas (5-6 d) can be considered.
- Breastfeeding
- Breast milk contains many substances that promote bowel growth and antagonize bacteria.
- Strong evidence in the literature demonstrates that the continued use of breast milk is actually beneficial in children with acute diarrhea.
- Thus, encourage that breastfeeding continue throughout illness, providing additional OR solution while diarrheal output persists.
Diarrheal diseases have been the object of numerous forms of treatment, both dietetic and pharmacologic, for centuries. However, the evidence is now clear that, in most cases, the best option for treatment of acute-onset diarrhea is the early use of ORT. Pharmacological treatment is rarely of any use, and drugs are often harmful.
Drug Category: Antibiotic and antiparasitics agents
Antimicrobial agents, in addition to the immune system, help destroy offending organisms. Their use is confined to specific etiologies and/or clinical circumstances.
| Drug Name | Cefixime (Suprax) |
| Description | Potent long-acting oral cephalosporin with increased gram-negative coverage. Inhibits bacterial cell wall synthesis by binding to 1 or more PBPs. Bacteria eventually lyse because of ongoing activity of cell wall autolytic enzymes while cell wall assembly is arrested. |
| Adult Dose | 400 mg/d PO qd for 7-10 d |
| Pediatric Dose | 8 mg/kg/d PO qd for 7-10 d |
| Contraindications | Documented hypersensitivity |
| Interactions | Aminoglycosides increase nephrotoxic potential; probenecid may increase effects by decreasing clearance |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
|
| Precautions | Documented hypersensitivity to penicillins; reduced renal function; administer with food to minimize nausea and diarrhea |
| Drug Name | Ceftriaxone (Rocephin) |
| Description | A third-generation cephalosporin antibiotic with activity against gram-positive and some gram-negative bacteria. Binds to PBPs, inhibiting bacterial cell wall growth. |
| Adult Dose | 1-2 g IV/IM q24h |
| Pediatric Dose | 50 mg/kg/d IV/IM divided qd/bid for 7-10 d; not to exceed 2 g/d |
| Contraindications | Documented hypersensitivity; do not use in neonates who are hyperbilirubinemic |
| Interactions | Probenecid increases ceftriaxone serum concentration |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
|
| Precautions | Caution in patients with allergies to penicillin antibiotics; may cause skin rashes, diarrhea, and pain at site of injection |
| Drug Name | Cefotaxime (Claforan) |
| Description | Third-generation cephalosporin antibiotic with activity against gram-positive and some gram-negative bacteria. Binds to PBPs, inhibiting bacterial cell wall growth. |
| Adult Dose | 1-2 g IV/IM q6-8h for 7-10 d |
| Pediatric Dose | 50 mg/kg/dose IV/IM tid for 7-10 d |
| Contraindications | Documented hypersensitivity |
| Interactions | Probenecid may increase levels; coadministration with furosemide and aminoglycosides may increase nephrotoxicity |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
|
| Precautions | Caution in patients with allergies to penicillin antibiotics; may cause rashes, thrombophlebitis, and GI upset (eg, nausea, vomiting, diarrhea) |
| Drug Name | Erythromycin (E.E.S., E-Mycin, Eryc, Ery-Tab, Erythrocin) |
| Description | Bacteriostatic macrolide with activity against most gram-positive organisms and atypical respiratory organisms. Useful for Campylobacter species and vibrio enteritis. |
| Adult Dose | 250-500 mg (base, stearate, or estolate) PO qid 400-800 mg (ethylsuccinate) PO qid |
| Pediatric Dose | 50 mg/kg/d PO/IV divided qid for 7-10 d |
| Contraindications | Documented hypersensitivity; hepatic impairment; inhibits CYP3A4, caution with concomitant administration of CYP3A4 substrates (eg, terfenadine, cisapride, astemizole) |
| Interactions | Coadministration may increase toxicity of theophylline, digoxin, carbamazepine, and cyclosporine; may potentiate anticoagulant effects of warfarin; coadministration with lovastatin and simvastatin increases risk of rhabdomyolysis |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
|
| Precautions | Caution in liver disease; estolate formulation may cause cholestatic jaundice; GI adverse effects are common (administer pc); discontinue use if nausea, vomiting, malaise, abdominal colic, or fever occurs |
| Drug Name | Furazolidone (Furoxone) |
| Description | Antiparasitic agent with wide coverage. Nitrofuran with antiprotozoal activity. Alternative drug for children because availability in liquid suspension. Most common adverse effects are GI upset and brown discoloration of urine. |
| Adult Dose | 100 mg PO qid for 7-10 d |
| Pediatric Dose | 5 mg/kg/d PO divided qid for 7-10 d |
| Contraindications | Documented hypersensitivity |
| Interactions | Increases levodopa blood concentrations and, thus, potential for toxicity; causes disulfiramlike reactions when taken with alcohol; toxicity of meperidine, paroxetine, fluoxetine, sertraline, trazodone, MAOIs, sympathomimetic amines, and TCAs increases when taken with furazolidone |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
|
| Precautions | Caution in G-6-PD deficiency when administering prolonged treatments; inhibits enzyme monoamine oxidase; may cause rashes, thrombophlebitis, and GI upset (eg, nausea, vomiting, diarrhea) |
| Drug Name | Iodoquinol (Vytone, Yodoxin) |
| Description | Antiparasitic agents with wide coverage. |
| Adult Dose | 650 mg PO tid pc for 20 d |
| Pediatric Dose | 30-40 mg/kg/d PO divided tid pc for 20 d; not to exceed adult dose |
| Contraindications | Documented hypersensitivity; preexisting optic neuropathy or hepatic damage |
| Interactions | None reported |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
|
| Precautions | Avoid long-term use; commonly causes nausea, vomiting, stomach pain, and diarrhea |
| Drug Name | Metronidazole (Flagyl) |
| Description | Very active against Giardia species, gram-negative anaerobes, and Entamoeba species. Imidazole ring-based antibiotic active against various anaerobic bacteria and protozoa. Often used in combination with other antimicrobial agents except for C difficile enterocolitis). |
| Adult Dose | 250-500 mg PO tid for 10 d |
| Pediatric Dose | 30-50 mg/kg/d PO divided tid for 10 d; not to exceed adult dose |
| Contraindications | Documented hypersensitivity |
| Interactions | May increase toxicity of anticoagulants, lithium, and phenytoin; cimetidine may increase toxicity of metronidazole; disulfiramlike reaction may occur with orally ingested ethanol |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
|
| Precautions | Do not use in pregnancy during first trimester; adjust dose in hepatic disease; monitor for seizures and development of peripheral neuropathy |
| Drug Name | Paromomycin (Humatin) |
| Description | Amebicidal and antibacterial aminoglycoside obtained from a strain of Streptomyces rimosus, active in intestinal amebiasis. Recommended for treatment of Diphyllobothrium latum, Taenia saginata, T solium, Dipylidium caninum, and Hymenolepis nana. |
| Adult Dose | 25-30 mg/kg/d PO divided tid for 7 d; not to exceed 4 g/d |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity; intestinal obstruction |
| Interactions | Nephrotoxic potential may increase with concurrent administration of other aminoglycosides, penicillins, cephalosporins, amphotericin B, and loop diuretics |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
|
| Precautions | Because of narrow therapeutic index and toxic hazards associated with extended administration, do not use for long-term therapy; caution in renal failure, hypocalcemia, myasthenia gravis, and conditions that depress neuromuscular transmission; adjust dose in renal impairment |
| Drug Name | Quinacrine (Atabrine) |
| Description | Very effective antiparasitic against Giardia species. |
| Adult Dose | 100 mg PO tid for 5-7 d |
| Pediatric Dose | 6 mg/kg/d PO divided tid for 5 d |
| Contraindications | Documented hypersensitivity; psoriasis |
| Interactions | Can cause disulfiram-type reaction when mixed with alcohol |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
|
| Precautions | Hemolysis (frequently dose-related) may occur in individuals who are G-6-PD deficient; may cause nausea, vomiting, abdominal pain, anorexia, and diarrhea; eczematous eruptions and discoloration of skin; poor palatability |
| Drug Name | Sulfamethoxazole and trimethoprim (Bactrim, Septra, Cotrim) |
| Description | Folate-synthesis blocker with wide antibiotic coverage. Inhibits bacterial growth by inhibiting synthesis of dihydrofolic acid. Effective in E coli infections. Dosage form contains 5:1 ratio of sulfamethoxazole to trimethoprim. |
| Adult Dose | 160 mg (based on trimethoprim component) PO bid for 7-10 d |
| Pediatric Dose | 10 mg/kg/d (based on trimethoprim component) PO bid for 7-10 d |
| Contraindications | Documented hypersensitivity; megaloblastic anemia due to folate deficiency |
| Interactions | May increase PT when used with warfarin (perform coagulation tests and adjust dose accordingly); coadministration with dapsone may increase blood levels of both drugs; coadministration of diuretics increases incidence of thrombocytopenia purpura in elderly individuals; phenytoin levels may increase with coadministration; may potentiate effects of methotrexate in bone marrow depression; hypoglycemic response to sulfonylureas may increase with coadministration; may increase levels of zidovudine |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
|
| Precautions | Do not use near term in pregnancy; discontinue at first appearance of rash or sign of adverse reaction; frequently obtain CBC counts; discontinue if significant hematologic changes occur; goiter, diuresis, and hypoglycemia may occur with sulfonamides; caution in folate deficiency (eg, persons with chronic alcoholism, elderly individuals, those receiving anticonvulsant therapy, those with malabsorption syndrome); hemolysis may occur in individuals who are G-6-PD deficient; patients with AIDS may not tolerate or respond; caution in renal or hepatic impairment (perform urinalyses and renal function tests during therapy); give fluids to prevent crystalluria and stone formation |
| Drug Name | Vancomycin (Vancocin) |
| Description | Effective treatment (when PO) for antibiotic-associated colitis due to C difficile. However, reserve for individuals whose symptoms are not responding to less expensive and almost equally effective metronidazole. |
| Adult Dose | 500 mg PO qid for 10-14 d |
| Pediatric Dose | 40-50 mg/kg/d PO divided qid for 10-14 d; not to exceed 2 g/d |
| Contraindications | Documented hypersensitivity |
| Interactions | None reported |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
|
| Precautions | IV preparation requires dose adjustment for renal failure, but PO form is absorbed poorly |
| Drug Name | Tetracycline (Sumycin) |
| Description | Treats gram-positive and gram-negative organisms as well as mycoplasmal, chlamydial, and rickettsial infections. Good agent in older children who present with severe Yersinia species infection. |
| Adult Dose | 250-500 mg PO q6h Mild-to-moderate infections: 500 mg PO bid or 250 mg PO qid for 7-14 d Severe infections: 500 mg PO qid for 7-14 d |
| Pediatric Dose | <8 years: Not recommended >8 years: 25-50 mg/kg/d (10-20 mg/lb) divided PO qid |
| Contraindications | Documented hypersensitivity; severe hepatic dysfunction |
| Interactions | Bioavailability decreases with antacids containing aluminum, calcium, magnesium, iron, or bismuth subsalicylate; can decrease effects of oral contraceptives, causing breakthrough bleeding and increased risk of pregnancy; can increase hypoprothrombinemic effects of anticoagulants |
| Pregnancy | D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus
|
| Precautions | Photosensitivity may occur with prolonged exposure to sunlight or tanning equipment; reduce dose in renal impairment; consider drug serum level determinations in prolonged therapy; use during tooth development (last one half of pregnancy through age 8 y) can cause permanent discoloration of teeth; Fanconilike syndrome may occur with outdated tetracyclines |
| Drug Name | Nitazoxanide (Alinia) |
| Description | Inhibits growth of C parvum sporozoites and oocysts and G lamblia trophozoites. Elicits antiprotozoal activity by interfering with pyruvate-ferredoxin oxidoreductase (PFOR) enzyme-dependent electron transfer reaction, which is essential to anaerobic energy metabolism. Available as a 20-mg/mL oral susp. |
| Adult Dose | 500 mg PO bid for 3 d |
| Pediatric Dose | <1 year: Not established 1-3 years: 100 mg (5 mL) PO q12h for 3 d with food 4-11 years: 200 mg (10 mL) PO q12h for 3 d with food >11 years: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | Tizoxanide (nitazoxanide metabolite) is >99.9% bound to plasma protein and may potentially increase toxicity of other highly plasma protein–bound drugs |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
|
| Precautions | May cause abdominal pain, diarrhea, vomiting, or headache; administer with food; caution when coadministered with other highly plasma protein–bound drugs with narrow therapeutic indices |
| Drug Name | Rifaximin (Xifaxan, RedActiv, Flonorm) |
| Description | Nonabsorbed ( <0.4%), broad-spectrum antibiotic specific for enteric pathogens of the gastrointestinal tract (ie, Gram-positive, Gram-negative, aerobic and anaerobic). Rifampin structural analog. Binds to beta-subunit of bacterial DNA-dependent RNA polymerase, thereby inhibiting RNA synthesis. Indicated for E coli (enterotoxigenic and enteroaggregative strains) associated with travelers' diarrhea. |
| Adult Dose | 200 mg PO tid |
| Pediatric Dose | <12 years: Not established >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity to rifaximin or rifamycin antimicrobial agents (eg, rifampin) |
| Interactions | Induces CYP450 3A4 in vitro; limited data exist; no significant interactions shown in single dose studies with midazolam and oral contraceptives |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
|
| Precautions | May promote intestinal bacterial overgrowth and cause superinfection; discontinue if diarrhea persists more than 24-48 h or worsens; seek immediate medical care if fever and/or bloody stools emerge (tablets not effective); not effective for travelers' diarrhea due to suspected pathogens other than E coli; postmarketing reports include allergic dermatitis, rash, angioneurotic edema, urticaria, and pruritus |
Drug Category: Vaccines
These agents elicit active immunization to increase resistance to infection. Vaccines consist of microorganisms or cellular components, which act as antigens. Administration of the vaccine stimulates the production of antibodies with specific protective properties.
| Drug Name | Rotavirus vaccine (RotaTeq, Rotarix) |
| Description | Currently, 2 orally administered live-virus vaccines are marketed in the United States. Both are indicated to prevent rotavirus gastroenteritis, a major cause of severe diarrhea in infants. RotaTeq is a pentavalent vaccine that contains 5 live reassortant rotaviruses and is administered as a 3-dose regimen against G1, G2, G3, and G4 serotypes, the 4 most common rotavirus group A serotypes. It also contains attachment protein P1A (genotype P[8]). Rotarix protects against rotavirus gastroenteritis caused by G1, G3, G4, and G9 strains and is administered as a 2-dose series in infants aged 6-24 wk. Clinical trials found that the vaccines prevented 74-78% of all rotavirus gastroenteritis cases, nearly all severe rotavirus gastroenteritis cases, and nearly all hospitalizations. |
| Adult Dose | Not indicated |
| Pediatric Dose | <6 weeks: Not established RotaTeq 6-12 weeks: 2 mL PO as a single dose, followed by 2 additional doses at 4- to 10-wk intervals; do not administer after age 32 wk Rotarix 6 weeks: 1 mL PO as a single dose; administer a second dose after an interval of at least 4 wk and before 24 wk of age
|
| Contraindications | Documented hypersensitivity; uncorrected congenital GI malformation that would predispose to intussusception |
| Interactions | Immunosuppressive therapies (eg, irradiation, antimetabolites, alkylating agents, cytotoxic drugs, high-dose corticosteroids) may decrease immune response |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
|
| Precautions | Common adverse effects include diarrhea, vomiting, otitis media, inflamed nasal passages, and bronchospasm; refrigerate and protect from light; handle and discard empty tube according to biological waste procedures; previously marketed rotavirus vaccine (RotaShield) was associated with intussusception; however, RotaTeq did not show an increased risk compared with placebo in clinical trials (monitor for signs of intestinal blockage), and Rotarix did not show an increase in intussusception in 31,673 infants compared with 31,552 infants who received placebo; do not mix in same syringe with other vaccines or solutions; febrile illness may be reason for delaying use except when, in the opinion of the physician, withholding the vaccine entails a greater risk; low-grade fever (<100.5°F [38.1°C]) itself and mild upper respiratory infection do not preclude vaccination |
Further Inpatient Care
- Admit neonates or young infants with moderate dehydration, suspected infection with enterohemorrhagic E coli, or bloody diarrhea.
- ORT is the universally recommended form of treatment, proven to be successful even in children who vomit or have mild-to-moderate dehydration. Admit a child with severe dehydration. Also, ORT requires vigilance. If the caregiver cannot comply with protocol, consider admission.
Further Outpatient Care
- Follow-up care depends on the severity of diarrhea and the child's age.
- Uncomplicated diarrhea in a school-aged child may not require follow-up care if the caregiver is reliable and has quick access to a physician.
- Closely monitor young children to ensure that complications do not occur.
- Closely monitor children who require labor-intensive ORT.
- Neonates require strict follow-up care within a few days of illness to ensure that malabsorption and dehydration do not occur.
Deterrence/Prevention
- Vaccination
- Vaccines are indicated for persons with high risk of exposure to some pathogens.
- In February 2006, the United States Food and Drug Administration (FDA) approved an oral vaccine for rotavirus (RotaTeq). It is currently the only vaccine approved in the United States for prevention of rotavirus gastroenteritis as of the date of this publication. On February 21, 2006, the American Academy of Pediatrics (AAP) and the Advisory Committee on Immunization Practices (ACIP) recommended RotaTeq to be part of regularly scheduled childhood immunizations. RotaTeq is administered in a 3-dose series starting between age 6-12 weeks and completing before 32 weeks. An older rotavirus vaccine (RotaShield) was associated with an increased incidence of intussusception and is no longer on the market, but RotaTeq did not show an increased risk compared with placebo in clinical trials.
- In April 2008, the FDA approved Rotarix, another oral vaccine, for prevention of rotavirus gastroenteritis. The current recommendation is to administer 2 separate doses of Rotarix to patients aged 6-24 weeks. Rotarix was efficacious in a large study, which reported that Rotarix protected patients with severe rotavirus gastroenteritis and decreased the rate of severe diarrhea or gastroenteritis of any cause.10
- A study that involved over 63,000 patients who received Rotarix or placebo at age 2 months and at age 4 months reported a decreased risk of intussusception in patients who received Rotarix.10 The intussusception data was determined over a 31-day observation period (inpatient or outpatient) after each dose of the Rotarix vaccine; this also included a 100-day surveillance period for all serious adverse events. Although more patients who received Rotarix were observed to have seizures or pneumonia-related deaths, this link has not been directly established to Rotarix. In addition, the FDA is requiring the Rotarix manufacturer to report data on postmarketing safety in a study that involves over 40,000 patients.
- The Salmonella typhi vaccine is recommended for travelers to countries with a high risk of this infection, persons with intimate exposure to a documented typhoid fever carrier, and workers with frequent exposure to this bacteria. Live-attenuated, killed whole-cell, and capsular polysaccharide vaccines are available.
- The Vibrio species vaccine is available but only protects 50% of immunized persons for 3-6 months. It is not indicated for use.
Complications
- Table 9 outlines common complications that can occur with various organisms.
Table 9. Common Complications Organism | Complications | Aeromonas caviae | Intussusception, gram-negative sepsis, HUS | Campylobacter species | Bacteremia, meningitis, cholecystitis, urinary tract infection, pancreatitis, Reiter syndrome (RS) | C difficile | Chronic diarrhea | C perfringens serotype C | Enteritis necroticans | Enterohemorrhagic E coli | Hemorrhagic colitis | Enterohemorrhagic E coli O157:H7 | HUS | Plesiomonas species | Septicemia | Salmonella species | Enteric fever, bacteremia, meningitis, osteomyelitis, myocarditis, RS | Shigella species | Seizures, HUS, perforation, RS | Vibrio species | Rapid dehydration | Yersinia enterocolitica | Appendicitis, perforation, intussusception, peritonitis, toxic megacolon, cholangitis, bacteremia, RS | Rotavirus | Isotonic dehydration, carbohydrate intolerance | Giardia species | Chronic fat malabsorption | Cryptosporidium species | Chronic diarrhea | Entamoeba species | Colonic perforation, liver abscess |
Enteric fever is caused by S typhi. This syndrome has an insidious onset of malaise, fever, abdominal pain, and bradycardia. Diarrhea and rash (rose spots) appear after 1 week of symptoms. Bacteria may have disseminated at that time, and treatment is required to prevent systemic complications such as hepatitis, myocarditis, cholecystitis, or GI bleeding. HUS is caused by damage to vascular endothelial cells by verotoxin (released by enterohemorrhagic E coli and by Shigella organisms). Thrombocytopenia, microangiopathic hemolytic anemia, and acute renal failure characterize HUS. Symptoms usually develop 1 week after onset of diarrhea, when the organism may be absent. RS can complicate acute infections and is characterized by arthritis, urethritis, conjunctivitis, and mucocutaneous lesions. Individuals with RS usually do not demonstrate all features. Carrier states are observed after some bacterial infections.
- After diarrhea caused by Salmonella organisms, 1-4% of individuals with nontyphoid and enteric fever infections become carriers. The carrier stage for Salmonella organisms is more likely for females, infants, and individuals with biliary tract disease.
- Asymptomatic C difficile carriage may be observed in as many as 20% of hospitalized patients receiving antibiotics and in 50% of infants.
- Rotavirus is excreted asymptomatically in feces of children who were previously infected, typically for up to 1-2 weeks.
Prognosis
- In developed countries, with proper management, prognosis is very good.
- Death is caused predominantly by dehydration and secondary malnutrition from a protracted course. Severe dehydration must be managed with parenteral fluids. Once malnutrition from secondary malabsorption begins, prognosis turns grim unless the patient is hospitalized and supplemental parenteral nutrition is started. Neonates and young infants are at particular risk of dehydration, malnutrition, and malabsorption syndromes.
- Even though the mortality rate is low in developed countries, children can die from complications; however, prognosis for children in countries without modern medical care and children with comorbid conditions is more guarded.
Patient Education
- AAP. 1997 Red Book. Report of the Committee on Infectious Disease. 24th ed. Elk Grove Village, IL: AAP; 1997.
- Bellemare S, Hartling L, Wiebe N, et al. Oral rehydration versus intravenous therapy for treating dehydration due to gastroenteritis in children: a meta-analysis of randomised controlled trials. BMC Med. Apr 15 2004;2:11. [Medline]. [Full Text].
- Charles MD, Holman RC, Curns AT, et al. Hospitalizations associated with rotavirus gastroenteritis in the United States, 1993-2002. Pediatr Infect Dis J. Jun 2006;25(6):489-93. [Medline].
- Duggan C, Nurko S. "Feeding the gut": the scientific basis for continued enteral nutrition during acute diarrhea. J Pediatr. Dec 1997;131(6):801-8. [Medline].
- Girard MP, Steele D, Chaignat CL, Kieny MP. A review of vaccine research and development: human enteric infections. Vaccine. Apr 5 2006;24(15):2732-50. [Medline].
- Guandalini S, Dincer AP. Nutritional management in diarrhoeal disease. Baillieres Clin Gastroenterol. Dec 1998;12(4):697-717. [Medline].
- Guandalini S. Treatment of acute diarrhea in the new millennium. J Pediatr Gastroenterol Nutr. May 2000;30(5):486-9. [Medline].
- Guerrant RL. Cryptosporidiosis: an emerging, highly infectious threat. Emerg Infect Dis. Jan-Mar 1997;3(1):51-7. [Medline].
- Liebelt EL. Clinical and laboratory evaluation and management of children with vomiting, diarrhea, and dehydration. Curr Opin Pediatr. Oct 1998;10(5):461-9. [Medline].
- Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, et al. Safety and effi
|